Genprex Inc (NASDAQ:GNPX)
| 1.79 Delayed Data As of Aug 12 |  +0.29 / +19.33%Today’s Change | 1.17 Today|||52-Week Range 3.62 | +36.64% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $85.7M |
Company Description
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Contact Information
Genprex, Inc. 3300 Bee Cave Road Austin Texas 78746 |
Employees
Shareholders
| Mutual fund holders | 5.31% |
| Other institutional | 5.22% |
| Individual stakeholders | 14.32% |
Top Executives
| J. Rodney Varner | Executive Chairman, President, CEO & Secretary |
| Ryan M. Confer | Chief Financial Officer |
| Mark S. Berger | Chief Medical Officer |
| Hemant Kumar | Chief Manufacturing & Technology Officer |
| Kate Combs | Senior Director-Clinical Operations |
